Log in

NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

$32.05
-0.55 (-1.69 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$31.82
Now: $32.05
$32.90
50-Day Range
$25.59
MA: $28.45
$32.60
52-Week Range
$15.48
Now: $32.05
$33.21
Volume810,344 shs
Average Volume897,396 shs
Market Capitalization$3.35 billion
P/E Ratio246.54
Dividend YieldN/A
Beta1.06
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. Read More…

Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$276.74 million
Cash Flow$0.32 per share
Book Value$3.43 per share

Profitability

Net Income$2.64 million

Miscellaneous

Employees1,500
Market Cap$3.35 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.


NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The medical research company had revenue of $104.70 million for the quarter, compared to analysts' expectations of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The company's revenue was up 51.5% compared to the same quarter last year. During the same period last year, the business earned $0.05 EPS. View NeoGenomics' Earnings History.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

What price target have analysts set for NEO?

6 Wall Street analysts have issued 1-year price objectives for NeoGenomics' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate NeoGenomics' share price to reach $22.60 in the next year. This suggests that the stock has a possible downside of 29.5%. View Analyst Price Targets for NeoGenomics.

What is the consensus analysts' recommendation for NeoGenomics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Has NeoGenomics been receiving favorable news coverage?

Press coverage about NEO stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for NeoGenomics.

Are investors shorting NeoGenomics?

NeoGenomics saw a increase in short interest in December. As of December 31st, there was short interest totalling 6,920,000 shares, an increase of 9.1% from the December 15th total of 6,340,000 shares. Based on an average daily trading volume, of 678,300 shares, the days-to-cover ratio is currently 10.2 days. Currently, 7.0% of the shares of the company are sold short. View NeoGenomics' Current Options Chain.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Marvell Technology Group (MRVL), Micron Technology (MU), Netflix (NFLX), Amarin (AMRN), Canopy Growth (CGC), CVS Health (CVS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
  • Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
  • Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
  • Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (0.35%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%), HWG Holdings LP (0.01%), OLD National Bancorp IN (0.01%) and Sciencast Management LP (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

Which institutional investors are buying NeoGenomics stock?

NEO stock was purchased by a variety of institutional investors in the last quarter, including HWG Holdings LP, OLD National Bancorp IN and Sciencast Management LP. View Insider Buying and Selling for NeoGenomics.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $32.05.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $3.35 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

What is NeoGenomics' official website?

The official website for NeoGenomics is http://www.neogenomics.com/.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]


MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel